DYN Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.93 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.1% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Dyne Therapeutics, Inc.
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases.
Sector
Healthcare
Industry
Biotechnology
Held By 3 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.